


=> d l1 sia
 L1 HAS NO ANSWERS
 L1 STR

10/506921



VAR G1=ME/ET
 NODE ATTRIBUTES:
 HCOUNT IS E2 AT 2
 HCOUNT IS E2 AT 5
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

=> d his

(FILE 'HOME' ENTERED AT 15:37:05 ON 02 NOV 2006)

FILE 'REGISTRY' ENTERED AT 15:37:17 ON 02 NOV 2006

L1 STR
 L2 1 S L1
 L3 8 S L1 FUL


=> d 1 sub bib abs

L3 ANSWER 1 OF 8 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 593251-95-7 REGISTRY
 ED Entered STN: 26 Sep 2003
 CN 3,5-Hexadien-2-one, 6-[(1aR,2R,3S,3aS,5R,6R,7aR,7bS)-decahydro-5,6-dihydroxy-1a,6-dimethyl-2-[(1E)-1-methyl-1-propenyl]naphth[1,2-b]oxiren-3-yl]-3-methyl-, (3E,5E)-rel- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Angiogenesis inhibitor F-1491H
 CN ICM 0301H
 FS STEREOSEARCH
 MF C23 H34 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Relative stereochemistry.
 Double bond geometry as shown.
 Currently available stereo shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 141:310347 CA
TI ICM0301s, new angiogenesis inhibitors from *Aspergillus* sp. F-1491. I.
Taxonomy, fermentation, isolation and biological activities
AU Kumagai, Hiroyuki; Someno, Tetsuya; Dobashi, Kazuyuki; Isshiki, Kunio;
Ishizuka, Masaaki; Ikeda, Daishiro
CS Microbial Chemistry Research Center, Numazu Bio-Medical Research
Institute, Numazu, 410-0301, Japan
SO Journal of Antibiotics (2004), 57(2), 97-103
CODEN: JANTAJ; ISSN: 0021-8820
PB Japan Antibiotics Research Association
DT Journal
LA English
GI



AB In the course of screening program for inhibitors of angiogenesis, 8 novel substances designated as ICM0301A-H were isolated from the culture broth of *Aspergillus* sp. F-1491. ICM0301s inhibited the growth of human umbilical vein endothelial cells (HUVECs) induced by basic fibroblast growth factor (bFGF) with IC₅₀ values of 2.2-9.3 µg/mL. ICM0301A (I) showed significant anti-angiogenic activity at lower than 10 µg/mL in the angiogenesis model using rat aorta cultured in fibrin gel. ICM0301s showed very low cytotoxicity against various tumor cells. Furthermore, I

did not show any toxic symptom in mice by i.p. injection at 100 mg/kg.
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


REFERENCE 2

AN 140:423498 CA
TI ICM0301s, new angiogenesis inhibitors from Aspergillus sp. F-1491. II. Physico-chemical properties and structure elucidation
AU Someno, Tetsuya; Kumagai, Hiroyuki; Ohba, Shun-ichi; Amemiya, Masahide; Naganawa, Hiroshi; Ishizuka, Masaaki; Ikeda, Daishiro
CS Microbial Chemistry Research Center, Numazu Bio-Medical Research Institute, Numazu, 410-0301, Japan
SO Journal of Antibiotics (2004), 57(2), 104-109
CODEN: JANTAJ; ISSN: 0021-8820
PB Japan Antibiotics Research Association
DT Journal
LA English
AB ICM0301A, B, and their congeners were previously isolated from a culture broth of Aspergillus sp. F-1491 as new angiogenesis inhibitors. Their structures were elucidated by spectroscopic analyses. ICM0301A and B have a substituted decalin skeleton containing two oxirane rings.
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 3

AN 139:229344 CA
TI Angiogenesis inhibitors manufacture with Aspergillus
IN Kumagai, Hiroyuki; Sameshima, Tomohiro; Matsufuji, Motoko; Kawamura, Naoto; Someno, Tetsuya; Ishizuka, Masaaki; Takeuchi, Tomio
PA Mercian Corporation, Japan; Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003076638	A1	20030918	WO 2003-JP2634	20030306
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU	2003221324	A1	20030922	AU 2003-221324	20030306
EP	1489186	A1	20041222	EP 2003-710259	20030306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US	2005131061	A1	20050616	US 2003-506976	20030306
PRAI	JP 2002-63059		20020308		
	WO 2003-JP2634		20030306		
GI					



AB The angiogenesis inhibitors (I: R = Me or ethyl; R1 = H, Cl, etc.; R2 = OH, or R1 and R2 form epoxy ring) are manufactured with Aspergillus by fermentation

F1491A-H are manufactured with the Aspergillus, and purified from the fermentation broth by solvent extraction and chromatogs. The physicochem. characteristics of these eight F-1491 compds. and physiol. and morphol. characteristics of the Aspergillus were also given.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>